RESEARCH TRIANGLE PARK, N.C. – RTI Health Solutions (RTI-HS) is pleased to announce the promotion of Beth Sherrill, MS to Global Head of Biostatistics.
Ms. Sherrill has more than 15 years of professional experience analyzing pharmaceutical and health-related data. In her previous role as director for biostatistics she brought insight and expertise to multiple clients in the pharmaceutical industry. She provides senior leadership to a team of statisticians in the US and the UK, applying advanced biostatistical techniques to issues in drug development, epidemiology, health care utilization, and outcomes research.
“I am delighted to have Beth lead our biostatistics group", said Elizabeth Andrews, PhD, Vice President, Pharmacoepidemiology and Risk Management. "She brings astute leadership skills, broad statistical expertise, and the vision to lead a diverse and growing business”.
Ms. Sherrill started her career as an industry biostatistician designing and analyzing phase 2/3 clinical trials for international submissions and is familiar with regulatory requirements for drug approval. In the past 10 years, she has broadened her experience in postmarketing studies such as epidemiologic analyses from disease registries, econometric work with claims databases, and large patient surveys. She has extensive experience with the use of propensity scoring, meta-analysis and proportional hazards modeling, working in complex disease areas such as oncology. Ms. Sherrill’s recent publications in British Journal of Cancer focus on endpoints and quality-of-life (QOL) measures for breast cancer studies.
(British Journal of Cancer, 99(10):1572-1578) and British Journal of Cancer, 99(5):711-715).
“The strength of our team lies in the breadth of our study experience” says Beth Sherrill. “Our statisticians work on a wide array of issues that require thinking outside the box, ranging from QOL concerns to safety surveillance to health care utilization. This is not your typical CRO.”
About RTI Health Solutions
RTI Health Solutions provides scientifically rigorous research and consulting service in health economics, health outcomes, psychometrics, pricing and reimbursement, health preference assessment, epidemiology, pharmacovigilance, clinical development, and biostatistics to help biopharmaceutical companies successfully develop and gain market approval for their products.